Combination treatment for steroid-dependent uveitis
Treatments studied
Part of Eyes & vision clinical trials.
This study tests a combination of two medicines, mycophenolate mofetil and adalimumab, to help control eye inflammation (uveitis) and reduce the need for steroids. It is for people who still have active inflammation despite taking a steroid medication like prednisone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a type of eye inflammation called non-infectious intermediate, posterior, or pan-uveitis.
- You have had signs of active inflammation in the last 3 months, like swelling in the back of the eye or blurry vision.
- You have been taking a steroid like prednisone at a dose higher than 7 mg per day for these eye problems.
- You are willing to use effective birth control during the study and for a few months after treatment ends (if you or your partner can become pregnant).
- You have had a chest X-ray or CT scan in the last 12 weeks showing no active infections like tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two forms of the same medicine (adalimumab) to treat non-infectious uveitis, an inflammation inside the eye. It aims to see which delivery method works better to control active inflammation and protect vision.
This study tests a new cell therapy (TRX103) to see if it can safely reduce inflammation in people with active uveitis that is not caused by infection. The treatment aims to calm the immune system to control the disease and may help avoid long-term steroid use.
This study follows people with non-infectious uveitis (inflammation inside the eye) that affects the middle or back of the eye. It aims to understand the disease better and see how different treatments work, which may help improve future care.
This trial tests a different way of giving a steroid injection for eye swelling (macular edema) caused by uveitis. It is for people whose swelling hasn't improved with a standard steroid injection behind the eye.
This study tests a drug called adalimumab, which helps calm the immune system, when added to the steroid medicine you may already be taking. It aims to see if this combination is safe and works better for people with Behçet's disease that affects the back of the eye and has recently flared up.
This study compares two biologic medicines, adalimumab and tocilizumab, to see which works better for severe eye inflammation (uveitis) caused by Behçet's disease. Both are given as injections, and the goal is to improve vision and reduce eye damage.
Hear when a new Non Infectious Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.